Tuesday, November 14, 2023
Geneva, Switzerland
In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The fourth Global Biosimilars Week (GBW) will run from 13th to 17th November, 2023 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.
The campaign theme this year is Making Cancer Care More Accessible to Patients and Healthcare Systems. IGBA invites patients, healthcare professionals, government organisations and other interested parties to share their resources about biosimilar medicines using the hashtag #GlobalBiosimilarsWeek.
The highlight of the week is a complimentary webinar on Wednesday, November 15, hosted by The Center for Biosimilars (CFB®). During this event, it will be discussed how all stakeholders can collaborate to expand global cancer care, with a special focus on the role of policies related to biosimilar medicines.
IGBA companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been over 800 biosimilar approvals in IGBA’s membership jurisdictions and additional ICH Member countries, covering over 10 therapeutic areas. “Biosimilar medicine approvals have expanded, but we need purposeful biosimilar policies to expand access”, commented David Gaugh, Chair IGBA.
“We call all relevant stakeholders to join the Biosimilars Movement on advancing access. Patients around the world are desperately waiting. With good policies, we can turn together the tide on cancer”, added Suzette Kox, Secretariat General IGBA.
-ENDS-
Media inquiries:
Jannette Cotterell
Executive Counsel Australia
0419 204 059
jcotterell@executivecounsel.com.au
ABOUT IGBA
About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.
ABOUT GBMA
The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au
